Investors buoyed by positive data for Immutepâs immunotherapy
Save
Share
Small cap immunotherapy biotech Immutep is a step closer to commercialising its leading drug candidate, âeftiâ, after releasing promising data showing the effectiveness of the drug in treating various types of lung, head and neck, and solid tumour cancers.
Immutep CEO Marc Voigt says LAG-3 immunotherapies are now getting noticed by the biotech community.Â
The positive clinical trial data will be a boon for the business, which is already trading up 58.3 per cent for the year-to-date at 66¢, thanks to the growing interest from the global biotech community in the LAG-3 checkpoint, which Immutep is targeting. This interest has been driven by the progress that Bristol Myers Squibb has made with its own LAG-3 immunotherapy.